|Other Names||ATPase inhibitor, mitochondrial, Inhibitor of F(1)F(o)-ATPase, IF(1), IF1, ATPIF1, ATPI|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Endogenous F(1)F(o)-ATPase inhibitor limiting ATP depletion when the mitochondrial membrane potential falls below a threshold and the F(1)F(o)-ATP synthase starts hydrolyzing ATP to pump protons out of the mitochondrial matrix. Required to avoid the consumption of cellular ATP when the F(1)F(o)-ATP synthase enzyme acts as an ATP hydrolase. Indirectly acts as a regulator of heme synthesis in erythroid tissues: regulates heme synthesis by modulating the mitochondrial pH and redox potential, allowing FECH to efficiently catalyze the incorporation of iron into protoporphyrin IX to produce heme.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a mitochondrial ATPase inhibitor.Alternative splicing occurs at this locus and three transcriptvariants encoding distinct isoforms have been identified. [providedby RefSeq].
Sanchez-Cenizo, L., et al. J. Biol. Chem. 285(33):25308-25313(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Li, N., et al. Int. J. Neurosci. 120(3):217-221(2010)Contessi, S., et al. J. Bioenerg. Biomembr. 39(4):291-300(2007)Ma, J., et al. Atherosclerosis 191(1):63-72(2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.